D. Boral Capital Acted as Lead Placement Agent to Neo-Concept International Group Holdings Limited (Nasdaq:NCI) in Connection with its ~$8,000,000 Follow-On Offering ELEMENT--[Back to the Newsroom]# D. Boral Capital Acted as Lead Placement Agent to Neo-Concept International Group Holdings Limited (Nasdaq:NCI) in Connection with its ~$8,000,000 Follow-On OfferingNEW YORK CITY, NEW YORK / [ACCESS Newswire]/ February 24, 2026 / On February 11, 2026, Neo-Concept International Group Holdings Limited (Nasdaq:NCI) ...

Core Viewpoint - D. Boral Acquisition I Corp. successfully closed its initial public offering (IPO) of 28,750,000 units, raising total gross proceeds of $287,500,000, with units trading on The Nasdaq Global Market under the ticker symbol "DBCAU" [1] Group 1 - The IPO included 3,750,000 units from the underwriters' over-allotment option, priced at $10.00 per unit [1] - Each unit consists of one Class A ordinary share and one-half of one redeemable public warrant, with whole warrants allowing the purchase of one Class A ordinary share at $11.50 [1] - The Class A ordinary shares and warrants are expected to trade separately under the symbols "DBCA" and "DBCAW" respectively [1] Group 2 - The net proceeds from the offering will be used to pursue and complete a business combination with one or more businesses [2] - D. Boral Capital LLC served as the sole book-running manager for the offering, while Loeb & Loeb LLP and Paul Hastings LLP acted as legal counsel [2] Group 3 - The company was formed to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses [5] - The company intends to focus on industries that complement its management team's background and leverage their ability to identify and acquire businesses [5]

As filed with the U.S. Securities and Exchange Commission on January 29, 2026. Registration No. 333-290920 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aeon Acquisition I Corp. (Exact name of registrant as specified in its charter) Cayman Islands 6770 N/A (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identifi ...

As filed with the U.S. Securities and Exchange Commission on January 28, 2026. Registration No. 333-291613 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ______________________________________ D. Boral Acquisition I Corp. (Exact name of registrant as specified in its charter) ______________________________________ British Virgin Islands 6770 N/A (State or other ...

Core Viewpoint - GlobalTech Corporation has announced the planned acquisition of 123 Investments Limited, operating as Moda in Pelle, with D. Boral Capital LLC serving as its strategic advisor for this transaction [1][2]. Company Overview - GlobalTech Corporation is a U.S.-based technology holding company focused on artificial intelligence, big data, and emerging technologies, aiming to empower innovative companies through strategic partnerships and capital investment [3]. - D. Boral Capital LLC is a global investment bank that specializes in providing strategic advisory and financial solutions to middle-market and emerging growth companies, having successfully aggregated approximately $30 billion in capital since its inception in 2020 [4][3]. Acquisition Details - The acquisition of Moda in Pelle is part of GlobalTech's strategy to scale globally and invest in cutting-edge solutions, with updates to be shared in future public filings [2]. - The transaction is subject to customary agreements and compliance, with no assurance of timely completion [2]. Moda in Pelle Overview - Moda in Pelle, established in 1975, is a British footwear brand known for its high-quality products and strong presence in the UK market, operating over 40 retail stores and a robust online platform [4].

As filed with the United States Securities and Exchange Commission on December 9, 2025 under the Securities Act of 1933, as amended. Registration No. 333-290350 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ––––––––––––––––––––––––––––––––––––––– AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ––––––––––––––––––––––––––––––––––––––– K2 Capital Acquisition Corporation (Exact name of registrant as specified in its charter) ––––––––––––––––––––––––– ...

As filed with the U.S. Securities and Exchange Commission on November 18, 2025. Registration No. 333-[_____] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ______________________________________ D. Boral Acquisition I Corp. (Exact name of registrant as specified in its charter) ______________________________________ British Virgin Islands 6770 N/A (State or other jurisdiction of incorporation or organization) (Primary ...

Core Insights - The company, Yikatong Technology, has entered into a securities subscription agreement with ATW Partners, allowing it to issue up to $150 million in convertible bonds [1][3] - The investment aims to enhance the company's financial strength and flexibility to support its global core strategy [1] - The raised funds will primarily be used for global business growth, accelerating product innovation, deepening partnerships with leading automotive brands, and investing in core areas such as software-defined vehicles and intelligent cockpit technology [1] Company Statements - The co-founder and CEO of Yikatong Technology, Shen Ziyu, stated that the subscription reflects institutional investors' confidence in the company's technological leadership and globalization strategy [3] - The new investment will strengthen the company's financial stability and advance the development of next-generation mobility solutions [3] - The exclusive placement agent for this issuance is D. Boral Capital LLC [3]

Core Insights - ECARX Holdings Inc. has entered into a securities purchase agreement with ATW Partners to issue convertible notes totaling up to $150 million, aimed at enhancing liquidity and strengthening its balance sheet [1][2] Financial Position - The financing is expected to improve ECARX's liquidity and provide financial flexibility for strategic priorities, including global expansion and product innovation [2] - The proceeds will support investments in software-defined vehicle and intelligent cockpit technologies [2] Company Overview - ECARX is a global automotive technology provider, delivering solutions for next-generation smart vehicles, including system on a chip (SoC) and central computing platforms [4] - Founded in 2017 and listed on Nasdaq in 2022, ECARX employs over 1,600 people across 13 locations worldwide [5] - The company has partnerships with major automakers, including Volkswagen Group and FAW Group, and its products are present in over 9.3 million vehicles globally [5]

Core Viewpoint - XORTX Therapeutics Inc. has successfully closed a registered direct offering, raising gross proceeds of US$1,102,500 for the sale of 1,750,000 common shares at a price of US$0.63 per share, which will be used for working capital and general corporate purposes [1][3]. Group 1: Offering Details - The offering included 572,470 common shares and 1,117,530 pre-funded warrants, with each warrant allowing the holder to acquire one common share at an exercise price of $0.001 [2]. - D. Boral Capital LLC acted as the sole placement agent for the offering and will receive 87,500 agent warrants, each exercisable into one common share at an exercise price of US$0.69 [4]. Group 2: Company Overview - XORTX is focused on developing innovative therapies for gout and progressive kidney disease, with three clinically advanced products: XRx-026 for gout, XRx-008 for ADPKD, and XRx-101 for acute kidney injury associated with respiratory virus infections [7]. - The company is also developing XRx-225, a pre-clinical program for Type 2 diabetic nephropathy, targeting purine metabolism and xanthine oxidase to reduce uric acid production [7].